Dare Bioscience, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Dare Bioscience, Inc. (DARE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.13 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-03-28
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-06-30 was $1.11, a 11.90% decline year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $1.38, a 38.67% decline year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-09-30 was $1.42, a 29.09% increase year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-06-30 was $1.26, a 29.90% increase year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.13, a 13.08% decline from fiscal 2022.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.30, a 35.32% decline from fiscal 2021.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $2.01, a 101.00% increase from fiscal 2020.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $1.00, a 33.33% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.13 10-K · filed 2024-03-28 | |||
| 2022-12-31 | $1.30 10-K · filed 2024-03-28 | |||
| 2022-06-30 | $1.11 10-Q · filed 2022-08-09 | $1.33 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $1.38 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $2.01 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $1.42 10-Q · filed 2021-11-10 | $2.02 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | $1.26 10-Q · filed 2021-08-12 | $2.06 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $2.25 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $1.00 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $1.10 10-Q · filed 2020-11-12 | $1.00 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $0.97 10-Q · filed 2020-08-12 | $1.00 10-Q · filed 2020-08-12 | ||
| 2020-03-31 | $1.00 10-Q · filed 2020-05-14 | |||
| 2019-12-31 | $0.75 10-K · filed 2021-03-30 | |||
| 2019-09-30 | $0.75 10-Q · filed 2019-11-12 | $0.75 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $0.86 10-Q · filed 2019-08-14 | $0.75 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $0.72 10-Q · filed 2019-05-14 | |||
| 2018-12-31 | $1.03 10-K · filed 2020-03-27 | |||
| 2018-09-30 | $1.03 10-Q · filed 2018-11-13 | $1.04 10-Q · filed 2018-11-13 | ||
| 2018-06-30 | $1.61 10-Q · filed 2018-08-13 | |||
| 2018-03-31 | $2.26 10-Q · filed 2018-05-14 | |||
| 2017-12-31 | $4.46 10-K · filed 2019-04-01 | |||
| 2015-09-30 | $4.22 10-Q · filed 2015-11-16 | |||
| 2015-06-30 | $7.81 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $5.07 10-Q · filed 2015-05-06 | |||
| 2014-09-30 | $2.41 10-Q · filed 2014-11-13 | $3.71 10-Q · filed 2015-11-16 | ||
| 2014-06-30 | $3.24 10-Q · filed 2014-08-12 | $3.82 10-Q · filed 2015-08-06 | ||
| 2014-03-31 | $5.95 10-Q · filed 2015-05-06 | |||
| 2013-09-30 | $2.61 10-Q · filed 2014-11-13 | |||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-12 | $2.67 10-Q · filed 2014-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |